Seamus Fernandez
Stock Analyst at Guggenheim
(3.57)
# 902
Out of 4,732 analysts
91
Total ratings
48.28%
Success rate
7.21%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $37.06 | - | 6 | Dec 12, 2024 | |
| CDTX Cidara Therapeutics | Initiates: Buy | $33 | $21.70 | +52.07% | 1 | Nov 8, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $97.92 | +32.76% | 13 | Nov 6, 2024 | |
| GSK GSK | Downgrades: Neutral | n/a | $33.43 | - | 2 | Oct 31, 2024 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Buy | $70 | $54.54 | +28.35% | 1 | Oct 21, 2024 | |
| TENX Tenax Therapeutics | Initiates: Buy | $16 | $6.37 | +151.19% | 1 | Oct 14, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $44 | $9.89 | +344.89% | 1 | Oct 8, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $884 → $1,030 | $725.72 | +41.93% | 14 | Aug 16, 2024 | |
| RVNC Revance Therapeutics | Downgrades: Neutral | n/a | $3.68 | - | 1 | Aug 12, 2024 | |
| HLVX HilleVax | Downgrades: Neutral | n/a | $1.90 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.86 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $55 | $6.14 | +795.77% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $16.79 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $9.24 | +246.32% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $65 | $85.30 | -23.80% | 2 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $27.06 | +84.77% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $56.29 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $78.69 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $97.53 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.66 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $126.20 | -78.61% | 4 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.57 | +2,001.17% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $23.78 | +89.23% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $66.60 | -42.94% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $26.30 | +44.49% | 3 | Jan 31, 2018 |
Apogee Therapeutics
Dec 12, 2024
Reiterates: Buy
Price Target: n/a
Current: $37.06
Upside: -
Cidara Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $33
Current: $21.70
Upside: +52.07%
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $97.92
Upside: +32.76%
GSK
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $33.43
Upside: -
Rhythm Pharmaceuticals
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $54.54
Upside: +28.35%
Tenax Therapeutics
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $6.37
Upside: +151.19%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $44
Current: $9.89
Upside: +344.89%
Eli Lilly
Aug 16, 2024
Maintains: Buy
Price Target: $884 → $1,030
Current: $725.72
Upside: +41.93%
Revance Therapeutics
Aug 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.68
Upside: -
HilleVax
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.90
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.86
Upside: -
Aug 15, 2023
Maintains: Buy
Price Target: $56 → $55
Current: $6.14
Upside: +795.77%
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $16.79
Upside: -
Mar 7, 2023
Initiates: Buy
Price Target: $32
Current: $9.24
Upside: +246.32%
Feb 28, 2023
Maintains: Buy
Price Target: $66 → $65
Current: $85.30
Upside: -23.80%
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $27.06
Upside: +84.77%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $56.29
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $78.69
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $97.53
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.66
Upside: -
Nov 15, 2018
Initiates: Outperform
Price Target: $27
Current: $126.20
Upside: -78.61%
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.57
Upside: +2,001.17%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $23.78
Upside: +89.23%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $66.60
Upside: -42.94%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $26.30
Upside: +44.49%